JP2008535835A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535835A5
JP2008535835A5 JP2008505262A JP2008505262A JP2008535835A5 JP 2008535835 A5 JP2008535835 A5 JP 2008535835A5 JP 2008505262 A JP2008505262 A JP 2008505262A JP 2008505262 A JP2008505262 A JP 2008505262A JP 2008535835 A5 JP2008535835 A5 JP 2008535835A5
Authority
JP
Japan
Prior art keywords
amino
formula
compound
thiazolo
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008505262A
Other languages
English (en)
Japanese (ja)
Other versions
JP5165553B2 (ja
JP2008535835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/000399 external-priority patent/WO2006107258A1/en
Publication of JP2008535835A publication Critical patent/JP2008535835A/ja
Publication of JP2008535835A5 publication Critical patent/JP2008535835A5/ja
Application granted granted Critical
Publication of JP5165553B2 publication Critical patent/JP5165553B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008505262A 2005-04-06 2006-04-03 新規な５−置換された７−アミノ［１，３］チアゾロ［４，５−ｄ］ピリミジン誘導体 Expired - Lifetime JP5165553B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06
SE0500767-9 2005-04-06
PCT/SE2006/000399 WO2006107258A1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2008535835A JP2008535835A (ja) 2008-09-04
JP2008535835A5 true JP2008535835A5 (enExample) 2009-06-04
JP5165553B2 JP5165553B2 (ja) 2013-03-21

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505262A Expired - Lifetime JP5165553B2 (ja) 2005-04-06 2006-04-03 新規な５−置換された７−アミノ［１，３］チアゾロ［４，５−ｄ］ピリミジン誘導体

Country Status (30)

Country Link
US (2) US7947693B2 (enExample)
EP (1) EP1869056B1 (enExample)
JP (1) JP5165553B2 (enExample)
KR (1) KR101335055B1 (enExample)
CN (1) CN101193897B (enExample)
AR (1) AR055890A1 (enExample)
AT (1) ATE487727T1 (enExample)
AU (1) AU2006231836B2 (enExample)
BR (1) BRPI0609738A2 (enExample)
CA (1) CA2604017C (enExample)
CY (1) CY1111316T1 (enExample)
DE (1) DE602006018124D1 (enExample)
DK (1) DK1869056T3 (enExample)
ES (1) ES2354450T3 (enExample)
HR (1) HRP20110047T1 (enExample)
IL (1) IL185912A0 (enExample)
MX (1) MX2007012060A (enExample)
NO (1) NO20075603L (enExample)
NZ (1) NZ561460A (enExample)
PL (1) PL1869056T3 (enExample)
PT (1) PT1869056E (enExample)
RS (1) RS51581B (enExample)
RU (1) RU2419623C2 (enExample)
SA (1) SA06270072B1 (enExample)
SI (1) SI1869056T1 (enExample)
TW (1) TW200714605A (enExample)
UA (1) UA90707C2 (enExample)
UY (1) UY29454A1 (enExample)
WO (1) WO2006107258A1 (enExample)
ZA (1) ZA200708187B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
CN101522693B (zh) 2006-09-29 2012-01-04 阿斯利康(瑞典)有限公司 5，7-二取代的[1，3]噻唑并[4，5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
WO2014142056A1 (ja) 2013-03-12 2014-09-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン－３－イル酢酸誘導体の塩およびその結晶
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20180222922A1 (en) * 2015-06-08 2018-08-09 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
PE20251587A1 (es) 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (enExample) * 1955-01-03
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
DK0891978T3 (da) * 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
WO1999051608A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
CA2330619A1 (en) 1998-05-01 1999-11-11 Eli Lilly And Company N1-modified glycopeptides
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
EP1589901A4 (en) * 2002-12-20 2006-08-09 Generipharm Inc INTRAKUTANE INJECTION
WO2005033115A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Similar Documents

Publication Publication Date Title
CA2604017A1 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
JP2008535834A5 (enExample)
US9133128B2 (en) Pyrazole derivatives as cannabinoid receptor 1 antagonists
TWI404721B (zh) 胺基－雜環化合物
CN1832948B (zh) 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
JP2024537824A5 (enExample)
JP2021532124A5 (enExample)
JP2017518981A5 (enExample)
JP2004528312A5 (enExample)
CN102387704A (zh) S1p5受体的激动剂和拮抗剂，和其用法
RU2007140552A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 5, 7-ДИЗАМЕЩЕННОГО [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3H)-ОНА
JP2005516067A5 (enExample)
KR20160038008A (ko) 브로모도메인 억제제로서 신규 퀴나졸리논
JP2014528433A5 (enExample)
JP2005536475A5 (enExample)
EA010596B1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
JP2006522747A5 (enExample)
JP2006522749A5 (enExample)
RU2005128775A (ru) Производные пиперидинбензолсульфамида
JP2004526788A5 (enExample)
JP2005525323A5 (enExample)
IL273169B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP2011500621A5 (enExample)
JP7661361B2 (ja) Ｉｌ－１７のモジュレーターとしてのイミダゾピリミジン
CA2660529A1 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders